Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice

BACKGROUND: Regorafenib is an orally administered multikinase inhibitor that has been approved for patients with chemotherapy-refractory metastatic colorectal cancer (mCRC). Even though regorafenib significantly improved survival in two international phase 3 trials (CORRECT and CONCUR), a high rate...

Descripción completa

Detalles Bibliográficos
Autores principales: Calcagno, Fabien, Lenoble, Sabrina, Lakkis, Zaher, Nguyen, Thierry, Limat, Samuel, Borg, Christophe, Jary, Marine, Kim, Stefano, Nerich, Virginie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933532/
https://www.ncbi.nlm.nih.gov/pubmed/27398042
http://dx.doi.org/10.4137/CMO.S38335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933532/
https://www.ncbi.nlm.nih.gov/pubmed/27398042
http://dx.doi.org/10.4137/CMO.S38335

Ejemplares similares